TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: ONESOURCE · data 2026-11-02
OneSource Specialty Pharma Limited
In plain words
Price: 17.5% below its 52-week high of ₹1,917.8.
Delivery: 48.2% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
Latest results: a net profit of ₹25 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,684 cr |
| Net profit (last 12 months) | ₹-2 cr |
| Sales growth, 3 years (yearly) | 232.4% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 30.5% (+0.7 pts in a year), pledged 38.8%, institutions 43.7%.
ROE -1.3%, ROCE -0.1%, operating margin 6.4%: how much profit it earns on the money it uses.
Debt/equity 0.26, Profit growth — and sales growth 232.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-1.3%).
- Promoters have pledged 38.8% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ONESOURCE Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹449.02 crore, up 37.2% YoY and up 4.9% QoQ.
Net profit was ₹25 crore, a turn to profit from a loss a year ago and up 443.5% QoQ.
Operating margin was 27.5% (27% a year ago).
EPS was ₹2.18, positive against a negative EPS a year ago and up 445% QoQ.
ONESOURCE के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹449.02 करोड़; पिछले साल की तुलना में 37.2% की बढ़त, पिछली तिमाही की तुलना में 4.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹25 करोड़; एक साल पहले के घाटे से मुनाफ़े में आया, पिछली तिमाही की तुलना में 443.5% की बढ़त।
ऑपरेटिंग मार्जिन: 27.5% (एक साल पहले 27%)।
EPS: ₹2.18; एक साल पहले के ऋणात्मक EPS से धनात्मक हुआ, पिछली तिमाही की तुलना में 445% की बढ़त।
ONESOURCEના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹449.02 કરોડ; ગયા વર્ષની સરખામણીએ 37.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.9% વધારો.
ચોખ્ખો નફો: ₹25 કરોડ; એક વર્ષ પહેલાંની ખોટમાંથી નફામાં આવી, ગયા ક્વાર્ટરની સરખામણીએ 443.5% વધારો.
ઓપરેટિંગ માર્જિન: 27.5% (એક વર્ષ પહેલાં 27%).
EPS: ₹2.18; એક વર્ષ પહેલાંના નકારાત્મક EPSથી હકારાત્મક થઈ, ગયા ક્વાર્ટરની સરખામણીએ 445% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
25/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 9/30: Delivery 30.1% over the last 20 sessions vs 49.0% in the 40 before (0.61x); shares delivered per day 1.86x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 12 schemes hold it, about ₹286 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 45/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 24 Jul 26Results Q1 FY27 results: turned to profit vs a year ago +2.1% next session
- 13 May 26Results Q4 FY26 results: profit −95.3% YoY -0.6% next session
- 23 Jan 26Results Q3 FY26 results: loss widened vs a year ago -25.5% next session
- 11 Nov 25Results Q2 FY26 results: turned to profit vs a year ago -1.9% next session
- 4 Aug 25Results Q1 FY26 results: net profit −₹0.2 cr +2.2% next session
- 5 May 25Results Q4 FY25 results: net profit ₹98.2 cr +1.9% next session
- 10 Feb 25Results Q2 FY25 results: net profit −₹39.3 cr -1.0% next session
- 29 Jan 25Results Q3 FY25 results: net profit −₹67 cr +5.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹449 cr | ₹25 cr | — | 27.5% | 2.18 |
| Mar 2026 | ₹428 cr | ₹5 cr | -95.3% | 21.5% | 0.4 |
| Dec 2025 | ₹290 cr | ₹-89 cr | — | 6.0% | -7.74 |
| Sept 2025 | ₹376 cr | ₹10 cr | — | 28.3% | 0.92 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 30.47% | 30.48% | 30.48% | 29.93% |
| Foreign institutions (FII) | 19.46% | 19.19% | 17.50% | 19.24% |
| Domestic institutions (DII) | 24.21% | 23.38% | 20.61% | 18.81% |
| Mutual funds | 13.76% | 12.98% | 10.13% | 9.02% |
| Retail investors | 9.95% | 9.31% | 9.76% | 9.49% |
| Number of shareholders | 79,770 | 77,899 | 79,460 | 84,595 |
Common questions
What was OneSource Specialty Pharma Limited's latest quarterly profit?
OneSource Specialty Pharma Limited reported a net profit of ₹25 cr for the quarter ended Jun 2026, on revenue of ₹449 cr.
How much do promoters hold in OneSource Specialty Pharma Limited?
Promoters held 30.47% of OneSource Specialty Pharma Limited at the end of Sept 2026, with 38.79% of promoter shares pledged.
Is OneSource Specialty Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.26.
What is the 52-week high and low of OneSource Specialty Pharma Limited?
The 52-week high is ₹1,917.8 and the 52-week low is ₹1,057.
Mutual funds holding OneSource Specialty Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 12 schemes holding about ₹286 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.01% | ₹105 cr |
| ADITYA BIRLA SUN LIFE VALUE FUND | Aditya Birla Sun Life Mutual Fund | 1.01% | ₹67 cr |
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 0.57% | ₹53 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.54% | ₹19 cr |
| Mirae Asset Multi Asset Allocation Fund | Mirae Asset Mutual Fund | 0.51% | ₹18 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.54% | ₹10 cr |
| ADITYA BIRLA SUN LIFE SPECIAL OPPORTUNITIES FUND | Aditya Birla Sun Life Mutual Fund | 0.64% | ₹9 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.41% | ₹5 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.54% | ₹0 cr |
| Mirae Asset BSE Select IPO ETF | Mirae Asset Mutual Fund | 0.87% | ₹0 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.89% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.54% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| OneSource Specialty Pharma Limited | ₹1,583.1 | ₹17,926 cr | — | 3.1 | -1.3% | -0.1% | 0.26 | -14.4% |
| Shilpa Medicare Limited | ₹935 | ₹18,671 cr | 61.5 | — | 9.8% | 9% | 0.25 | +159.7% |
| Caplin Point Laboratories Limited | ₹2,326.2 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +14.3% |
| Alivus Life Sciences Ltd | ₹1,447.5 | ₹17,284 cr | 26.6 | 4.9 | 18.4% | 22.4% | 0.02 | +59.4% |
| Cohance Lifesciences Ltd | ₹445.7 | ₹17,005 cr | 161.5 | 4.4 | 6.4% | 4.6% | 0.1 | -42.8% |
| PFIZER LIMITED | ₹3,630.6 | ₹16,867 cr | 22.6 | — | 17.2% | 20% | 0.02 | -31.8% |
Compare ONESOURCE with SHILPAMED in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ONESOURCE in TickerKhoj →